Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.78 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)4.12M
Market Cap
$15.30B
Enterprise Value$148.78M
Total Cash (Recent Filing)$361.31M
Total Debt (Recent Filing)£6.45M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Aug 06, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding742,665,900
10 Day Avg. Volume2,721,932
30 Day Avg. Volume4,122,515
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)6.49
Price to Sales (P/S)0.00
P/FCF Ratio-19.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$33.50Price Target Upside62.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Summit Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsGeographic consistency between China and ex-China regions should drive confidence in ivonescimab.
Market PositionThe collaboration between Bristol Myers Squibb and BioNTech lends more large pharma validation to the PD-(L)1 x VEGF class, which can positively impact SMMT.
Product PotentialIvonescimab’s progression-free survival is statistically significant and clinically meaningful, with a favorable toxicity profile compared to current second-line treatments.
Bears Say
Acquisition InterestSMMT loses a key potential acquirer with Bristol Myers Squibb backing BioNTech, reducing potential acquisition interest from large pharma companies.
Competitive LandscapeConsensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogeneous competitive landscape.
PartnershipsSummit is by far the worst-positioned and will need a major partnership beyond their antibody drug conjugate collaboration with Pfizer to succeed.
Ownership Overview
Currently, No data available
---
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $6.78 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $15.30B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 39 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on May 01, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.003.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 742,665,900 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 13.093%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.50 (62.62% Upside)
$33.50 (62.62% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 79.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
161.75%
12-Months-Change
Fundamentals
Return on Equity
-123.93%
Trailing 12-Months
Asset Growth
117.12%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, particularly the regulatory approval and promising interim results for ivonescimab, indicating strong progress in its clinical development. However, challenges such as limited market opportunities for specific trials and increased G&A expenses were noted. Overall, the positive highlights significantly outweigh the lowlights.Read More>SMMT Stock 12 Month Forecast
Average Price Target
$33.50
▲(62.62%Upside)